#Nuvalent hashtag - Bluesky

@newsen.bsky.social

4 days ago

Nuvalent Submits New Drug Application for Neladalkib to the FDA to Treat Advanced ALK-positive NSCLC Nuvalent has submitted a New Drug Application for neladalkib, targeting advanced ALK-positive NSCLC in TKI pre-treated patients, marking a key development in oncology.

Nuvalent Submits New Drug Application for Neladalkib to the FDA to Treat Advanced ALK-positive NSCLC #United_States #Cambridge #Nuvalent #Neladalkib #ALK-positive_NSCLC

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Nuvalent Unveils Promising Results for Zidesamtinib at AACR 2026 Annual Meeting Nuvalent, Inc. will present pivotal preclinical and clinical findings for Zidesamtinib, a new investigational cancer therapy, at the AACR 2026.

Nuvalent Unveils Promising Results for Zidesamtinib at AACR 2026 Annual Meeting #USA #San_Diego #Nuvalent #zidesamtinib #AACR2026

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

1 month ago

Nuvalent's Pipeline Progress and Financial Results for 2025: Aiming for New Heights in Oncology Treatments Nuvalent, Inc. has made significant strides in its oncology pipeline and reported its financial results for 2025, targeting FDA milestones and commercial launches.

Nuvalent's Pipeline Progress and Financial Results for 2025: Aiming for New Heights in Oncology Treatments #USA #Cambridge #Nuvalent #zidesamtinib #Neladalkib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Nuvalent to Showcase Innovations at the Upcoming Guggenheim Biotech Summit 2026 Nuvalent, Inc. announces its participation in the Guggenheim Emerging Outlook Biotech Summit 2026, highlighting its advancements in precision cancer therapies.

Nuvalent to Showcase Innovations at the Upcoming Guggenheim Biotech Summit 2026 #USA #New_York_City #biotech #cancer_therapies #Nuvalent

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

2 months ago

Nuvalent Marks Progress in OnTarget 2026 Operating Plan with New Milestones Nuvalent, Inc. highlights key milestones in its OnTarget 2026 plan, including FDA approval for zidesamtinib aimed at lung cancer treatment.

Nuvalent Marks Progress in OnTarget 2026 Operating Plan with New Milestones #United_States #Cambridge #Nuvalent #Lung_Cancer #zidesamtinib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

3 months ago

Nuvalent to Showcase Groundbreaking Cancer Therapies at J.P. Morgan Conference Nuvalent, a leading biopharmaceutical firm, will present its innovative cancer therapies at the J.P. Morgan Healthcare Conference, aiming to spotlight advancements in targeted treatments for kinase-related cancers.

Nuvalent to Showcase Groundbreaking Cancer Therapies at J.P. Morgan Conference #USA #cancer_therapy #San_Francisco #J.P._Morgan #Nuvalent

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent Strengthens Leadership with the Appointment of Ron Squarer to Its Board Nuvalent, Inc. enhances its Board of Directors with Ron Squarer's appointment, bringing extensive oncology experience to the company.

Nuvalent Strengthens Leadership with the Appointment of Ron Squarer to Its Board #USA #Cambridge #oncology #Nuvalent #Ron_Squarer

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent Set to Showcase Breakthrough Oncology Research at Upcoming Healthcare Conference Nuvalent, Inc., a leader in targeted cancer therapies, will participate in the Piper Sandler Annual Healthcare Conference, highlighting advancements in cutting-edge oncology research.

Nuvalent Set to Showcase Breakthrough Oncology Research at Upcoming Healthcare Conference #United_States #Cambridge #Cancer_Research #Nuvalent #targeted_therapies

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent Completes Successful Public Offering of Common Stock with Underwriters' Full Exercise Option Nuvalent, a biopharmaceutical firm, recently closed a public offering of shares, generating significant capital to fuel its cancer treatment innovations.

Nuvalent Completes Successful Public Offering of Common Stock with Underwriters' Full Exercise Option #United_States #Cambridge #cancer_therapies #Nuvalent #Class_A_Common_Stock

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent's Zidesamtinib Receives FDA Filing Acceptance for NSCLC Treatment Nuvalent, Inc. has announced that the FDA accepted its New Drug Application for zidesamtinib, targeting ROS1-positive NSCLC patients. This is a significant step in lung cancer treatment.

Nuvalent's Zidesamtinib Receives FDA Filing Acceptance for NSCLC Treatment #United_States #Cambridge #FDA #Nuvalent #zidesamtinib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent Sets Price for Public Offering of Common Stock Boosting Funds for Cancer Treatment Innovations Nuvalent, a clinical-stage biopharmaceutical company, announces the pricing of a public stock offering, aiming to raise substantial funds for advancing targeted cancer therapies.

Nuvalent Sets Price for Public Offering of Common Stock Boosting Funds for Cancer Treatment Innovations #Nuvalent #Inc #NUVL

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent, Inc. Launches Public Offering for Class A Common Stock Nuvalent, Inc., a biotech company, announces a public stock offering of Class A common shares valued at $500 million to fuel targeted cancer therapies.

Nuvalent, Inc. Launches Public Offering for Class A Common Stock #United_States #biopharmaceuticals #Cambridge #Nuvalent #stock_offering

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

4 months ago

Nuvalent's Neladalkib Shows Promise in ALK-Positive Lung Cancer Treatment Nuvalent reports positive trial data for Neladalkib, an ALK-targeting drug. The treatment showed effective response rates in ALK-positive lung cancer, signaling hope for patients.

Nuvalent's Neladalkib Shows Promise in ALK-Positive Lung Cancer Treatment #USA #Cambridge #Nuvalent #Neladalkib #ALK-positive

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Nuvalent Unveils Compelling Data on Zidesamtinib at 2025 ASCO Conference Nuvalent, Inc. will showcase phase 2 outcomes and pivotal safety data of Zidesamtinib at the upcoming IASLC ASCO North America Conference on Lung Cancer.

Nuvalent Unveils Compelling Data on Zidesamtinib at 2025 ASCO Conference #USA #Chicago #Nuvalent #zidesamtinib #ARROS-1

0 0 0 0

Nay ❌👑

@ravensongstudio.com

5 months ago

The Architects of Stability: A One-Year Reflection on Science and Gratitude My one-year scans just came in. The results are not a personal victory, but a testament to the vast, unseen system of human ingenuity that made them possible.

1 year ago, a 10cm mass was collapsing my airway. Today, my scans show it's gone.

I am overcome with humility. This isn't about me; it's about the Architects of Stability in science whose thankless work made this possible.

#Cancer #ALKPositive #ClinicalTrials #Neladalkib #Nuvalent #Gratitude

2 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Nuvalent Reports Promising Pipeline Developments and Q3 2025 Financial Outcomes Nuvalent, Inc. announces significant progress in its clinical pipeline and reveals Q3 2025 financial results, showcasing its commitment to targeted cancer therapies.

Nuvalent Reports Promising Pipeline Developments and Q3 2025 Financial Outcomes #United_States #Cambridge #Nuvalent #zidesamtinib #Neladalkib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Nuvalent Unveils Promising Data for Neladalkib in Treating Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 Nuvalent shares exciting preliminary findings on neladalkib's efficacy in treating advanced ALK-positive tumors beyond NSCLC during ESMO 2025.

Nuvalent Unveils Promising Data for Neladalkib in Treating Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025 #USA #Cambridge #Nuvalent #Neladalkib #ALK-positive_cancers

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

5 months ago

Nuvalent Unveils Promising Preclinical Data for HER2 Inhibitor NVL-330 at Prestigious Cancer Conference Nuvalent, Inc. showcases exciting preclinical findings for their HER2-selective inhibitor NVL-330 at the AACR-NCI-EORTC conference in Boston, aiming to redefine cancer treatment.

Nuvalent Unveils Promising Preclinical Data for HER2 Inhibitor NVL-330 at Prestigious Cancer Conference #USA #Cambridge #Nuvalent #NVL-330 #HER2

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

6 months ago

Nuvalent to Showcase Innovations at UBS 2025 Virtual Oncology Day Nuvalent, Inc. will present its groundbreaking work on targeted cancer therapies during the UBS 2025 Virtual Oncology Day, highlighting key executives.

Nuvalent to Showcase Innovations at UBS 2025 Virtual Oncology Day #United_States #Cambridge #cancer_therapy #oncology #Nuvalent

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Nuvalent Unveils Key Insights on Zidesamtinib for Advanced Lung Cancer Patients at WCLC 2025 Nuvalent has shared critical findings from the ARROS-1 trial on zidesamtinib for advanced ROS1-positive NSCLC patients at the WCLC 2025, highlighting its potential benefits.

Nuvalent Unveils Key Insights on Zidesamtinib for Advanced Lung Cancer Patients at WCLC 2025 #United_States #Cambridge #Nuvalent #zidesamtinib #ARROS-1

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Nuvalent Set to Shine at the Cantor Global Healthcare Conference 2025 Nuvalent, Inc. will present at the Cantor Global Healthcare Conference 2025, highlighting its targeted cancer therapies and engaging in a fireside chat.

Nuvalent Set to Shine at the Cantor Global Healthcare Conference 2025 #United_States #New_York #healthcare #Nuvalent #NUVL

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

7 months ago

Nuvalent Unveils Key Findings from ARROS-1 Clinical Trial of Zidesamtinib at Upcoming WCLC 2025 Nuvalent, Inc. is set to present findings from their ARROS-1 clinical trial on zidesamtinib for advanced ROS1-positive non-small cell lung cancer patients during the WCLC 2025.

Nuvalent Unveils Key Findings from ARROS-1 Clinical Trial of Zidesamtinib at Upcoming WCLC 2025 #United_States #Cambridge #Nuvalent #NSCLC #zidesamtinib

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

8 months ago

Nuvalent Launches ALKAZAR Phase 3 Study for Neladalkib in NSCLC Patients Nuvalent, Inc. has commenced its global Phase 3 trial, ALKAZAR, evaluating neladalkib for TKI-naïve patients with ALK-positive NSCLC, aiming to enhance treatment outcomes.

Nuvalent Launches ALKAZAR Phase 3 Study for Neladalkib in NSCLC Patients #USA #Cambridge #Nuvalent #Neladalkib #ALK-positive

0 0 0 0

pharmaphorum

@pharmaphorum.bsky.social

9 months ago

Nuvalent chases after Nuvation in ROS1 lung cancer New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

#Nuvalent has said it is on course to file for approval of its #ROS1inhibitor zidesamtinib as a #lungcancer treatment, although rival Nuvation Bio has beaten it to market.

pharmaphorum.com/news/nuvalen...

0 0 0 0

Thiard News@F4F

@newsen.bsky.social

9 months ago